according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Carcinogenicity (Inhalation) : Category 2

Specific target organ toxicity

- repeated exposure (Oral)

: Category 2 (Liver, Testis)

GHS label elements

Hazard pictograms :

Signal Word : Warning

Hazard Statements : H351 Suspected of causing cancer if inhaled.

H373 May cause damage to organs (Liver, Testis) through pro-

longed or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/06/2024 07/06/2024 76204-00028 Date of first issue: 03/17/2015 9.0

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data availa- ble	9004-34-6	>= 5 - < 10 *
Grazoprevir	No data availa- ble	1350462-55-3	>= 5 - < 10 *
Elbasvir	No data availa- ble	1370468-36-2	>= 1 - < 5 *
Magnesium stearate	Octadecanoic acid, magnesi- um salt (2:1)	557-04-0	>= 1 - < 5 *
Titanium dioxide	Titanic anhy- dride	13463-67-7	>= 0.1 - < 1 *

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

Wash with water and soap. In case of skin contact

Get medical attention if symptoms occur.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

Suspected of causing cancer if inhaled.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders First Aid responders should pay attention to self-protection,

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Chlorine compounds Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Grazoprevir	1350462-55- 3	TWA	85 μg/m3 (OEB 3)	Internal
		Wipe limit	850 μg/100 cm ²	Internal
Elbasvir	1370468-36- 2	TWA	150 μg/m3 (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m ³	CA AB OEL
		TWAEV	10 mg/m³	CA QC OEL

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/06/2024

 9.0
 07/06/2024
 76204-00028
 Date of first issue: 03/17/2015

		TWA (Inhal- able)	10 mg/m³	CA BC OEL
		TWA (Respirable)	3 mg/m³	CA BC OEL
		TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH
Titanium dioxide	13463-67-7	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m ³	CA QC OEL

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type
Hand protection

: Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n- : Not applicable

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

octanol/water

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Grazoprevir:

Result : No skin irritation

Elbasvir:

Species : reconstructed human epidermis (RhE)

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Grazoprevir:

Species : Bovine cornea Result : No eye irritation

Elbasvir:

Species : Bovine cornea Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Grazoprevir:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Dermal

Result : Not a skin sensitizer.

Elbasvir:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Dermal
Species : Mouse
Result : negative

Magnesium stearate:

Test Type : Maximization Test Routes of exposure : Skin contact

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Species Guinea pig

Method **OECD Test Guideline 406**

Result negative

Remarks Based on data from similar materials

Titanium dioxide:

Test Type Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species Mouse Result negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo Test Type: Mammalian erythrocyte micronucleus test (in vivo

> cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Grazoprevir:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo Test Type: In vivo micronucleus test

Application Route: Oral

Result: negative

Germ cell mutagenicity -

Weight of evidence does not support classification as a germ Assessment

cell mutagen.

Elbasvir:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo Test Type: In vivo micronucleus test

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Species: Rat

Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:

Cellulose:

Species: RatApplication Route: IngestionExposure time: 72 weeksResult: negative

Titanium dioxide:

Species : Rat

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : positive

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in inhalation studies with

animals.

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

П

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Grazoprevir:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: negative

Test Type: Multi-generation study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: No effects on fertility., No effects on fetal development.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight

Result: No effects on fetal development.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight

Result: No effects on fetal development.

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous

Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight

Result: No effects on fetal development.

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female

Application Route: Oral

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Fertility: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on early embryonic development.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on early embryonic development.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Components:

Grazoprevir:

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Grazoprevir:

Species Rat NOAEL 400 mg/kg Application Route Oral Exposure time : 30 Days

No significant adverse effects were reported Remarks

Species Rat NOAEL
Application Route
Exposure time 400 mg/kg : Oral

: 180 Days

Remarks No significant adverse effects were reported

NOAEL
LOAEL
Application Route
Exposure time
Target Organs Dog 15 mg/kg 100 mg/kg Oral 270 Days

Target Organs Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species Mouse NOAEL 200 mg/kg LOAEL 500 mg/kg Application Route Exposure time : Oral Exposure time 90 Days

Target Organs Liver, Kidney, Blood

Species NOAEL LOAEL Application Route Exposure time Target Organs Species Dog 20 mg/kg 600 mg/kg Oral 30 Days Target Organs Blood, Testis

Species Monkey NOAEL 10 mg/kg Exposure time 8 Days

Remarks No significant adverse effects were reported

Elbasvir:

Species Rat

NOAEL 1,000 mg/kg Application Route Oral Exposure time 180 d

Remarks No significant adverse effects were reported

Species Dog

NOAEL 1,000 mg/kg Application Route Oral Exposure time 270 d

Remarks No significant adverse effects were reported

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat

NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat NOAEL : 10 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea,

Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irrita-

tion, rhinitis, Drowsiness, nasal congestion

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Grazoprevir:

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10

mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10 mg/l

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

aquatic invertebrates Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 8.9 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 10

mg/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 10

mq/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 5 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1.3 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility.

LC50 (Menidia beryllina (Silverside)): > 10 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

LC50 (Americamysis): 7.7 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

plants

NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.84 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 271.9 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

: EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 66 % Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 37 % Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

Bioaccumulative potential

Components:

Grazoprevir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 7.62

Partition coefficient: n-

octanol/water

: log Pow: 3.72

Elbasvir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 82 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 6.54

Magnesium stearate:

Partition coefficient: n-

octanol/water

log Pow: > 4

Mobility in soil

Components:

Grazoprevir:

Distribution among environ-

mental compartments

log Koc: 4.01

Elbasvir:

Distribution among environ-

mental compartments

log Koc: 5.24

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/06/2024 07/06/2024 76204-00028 Date of first issue: 03/17/2015 9.0

(Elbasvir)

9 Class Ш Packing group Labels 9 Environmentally hazardous yes

IATA-DGR

UN/ID No. UN 3077

Proper shipping name Environmentally hazardous substance, solid, n.o.s.

(Elbasvir)

Class 9 Ш Packing group

Labels Miscellaneous

Packing instruction (cargo 956

aircraft)

Packing instruction (passen-956

ger aircraft)

Environmentally hazardous yes

IMDG-Code

UN 3077 UN number

ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, Proper shipping name

> N.O.S. (Elbasvir)

Class 9

Ш Packing group Labels 9

EmS Code F-A, S-F Marine pollutant yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number UN 3077

ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, Proper shipping name

N.O.S.

(Elbasvir)

Class 9 Packing group Ш Labels 9 **ERG Code** 171

Marine pollutant yes(Elbasvir)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 04/06/2024 9.0 07/06/2024 76204-00028 Date of first issue: 03/17/2015

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average CA AB OEL / TWA : 8-hour Occupational exposure limit CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

according to the Hazardous Products Regulations



Grazoprevir / Elbasvir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/06/2024 07/06/2024 76204-00028 Date of first issue: 03/17/2015 9.0

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date 07/06/2024 Date format mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8